Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Lymphoid 1

Conditions

Melanoma 8Sarcoma 6Breast Neoplasms 4Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Merkel Cell 2Skin Neoplasms 1Sarcoma, Kaposi 1Pleural Effusion, Malignant 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neurofibromatosis 1 1Neurofibromatoses 1Neurofibroma 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Ductal, Breast 1Carcinoma, Ductal 1Carcinoma, Basal Cell 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 12Radiotherapy 9avelumab 8Nivolumab 8cemiplimab 4Radiation 4Ipilimumab 4poly ICLC 3atezolizumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3talimogene laherparepvec 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Interferon-beta 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Cisplatin 2Carboplatin 2Biopsy 2veliparib 1vatalanib 1tremelimumab 1tocilizumab 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Merkel Cell × talimogene laherparepvec × Clear all
NCT02819843 2025-01-29

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
19 enrolled 7 charts
Dermatologic

Melanoma, Carcinoma, Merkel Cell

NCT03458117 2022-03-18

20139157 T-VEC

University of Zurich

Phase 1 Completed
26 enrolled
DermatologicLymphoid

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡